TR201111143T1 - NEW PHARMACEUTICAL CHOLINE PHENOFIBRATE COMPOSITIONS - Google Patents

NEW PHARMACEUTICAL CHOLINE PHENOFIBRATE COMPOSITIONS

Info

Publication number
TR201111143T1
TR201111143T1 TR2011/11143T TR201111143T TR201111143T1 TR 201111143 T1 TR201111143 T1 TR 201111143T1 TR 2011/11143 T TR2011/11143 T TR 2011/11143T TR 201111143 T TR201111143 T TR 201111143T TR 201111143 T1 TR201111143 T1 TR 201111143T1
Authority
TR
Turkey
Prior art keywords
choline
release
pharmaceutical
choline fenofibrate
phenofibrate
Prior art date
Application number
TR2011/11143T
Other languages
Turkish (tr)
Inventor
Rami̇ Reddy Kasu Raghu
Das Subhasis
Kumar Thommandru Vijaya
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of TR201111143T1 publication Critical patent/TR201111143T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Abstract

Salımı kontrollü farmasötik kolin fenofibrat bileşim(ler)i; bu bileşimler, kolin fenofibrat ve çeşitli yardımcı maddeler içeren bir merkez ve ayrıca, hızı kontrol eden ajan veya ajanlar içeren bir kaplama tabakasından meydana gelmektedir. Salımı kontrollü farmasötik kolin fenofibrat bileşim(ler)i, bu bileşimler, kolin fenofibrat ve bir veya daha fazla farmasötik yardımcı malzeme içeren suda çözünen inert madde içeren ve hemen salım sağlayan bir merkez ve aynca, hızı kontrol eden hidrofobik ajan veya ajanlar içeren bir kaplama tabakasından meydana gelir. Salımı kontrollü farmasötik kolin fenofibrat bileşim(ler)i; bu bileşimler, kolin fenofibrat ve bir veya daha fazla farmasötik yardımcı malzeme içeren suda çözünen inert madde içeren ve hemen salım sağlayan bir mericez ve aynca, hızı kontrol eden hidrofobik ajan veya ajanlar içeren bir kaplama tabakasından meydana gelir ve biyolojik olarak piyasada bulunan kolin fenofibrat (Trilipix®) formülasyonlarına eşdeğerdirler.Release controlled pharmaceutical choline fenofibrate composition (s); these compositions comprise a core comprising choline fenofibrate and various excipients as well as a coating layer comprising the rate controlling agent or agents. The release-controlled pharmaceutical choline fenofibrate composition (s) comprises a coating layer comprising a center which provides immediate release and also a rate-controlling hydrophobic agent or agents comprising choline fenofibrate and one or more pharmaceutical excipients, and an immediate release. it occurs. Release controlled pharmaceutical choline fenofibrate composition (s); these compositions comprise a release layer containing water-soluble inert materials containing choline fenofibrate and one or more pharmaceutical excipients, as well as immediate release, and a coating layer containing rate-controlling hydrophobic agent or agents, and the bioavailable choline phenofibrate (Trilipix). ®) formulations.

TR2011/11143T 2009-05-11 2010-05-10 NEW PHARMACEUTICAL CHOLINE PHENOFIBRATE COMPOSITIONS TR201111143T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN724KO2009 2009-05-11

Publications (1)

Publication Number Publication Date
TR201111143T1 true TR201111143T1 (en) 2012-05-21

Family

ID=42732802

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/11143T TR201111143T1 (en) 2009-05-11 2010-05-10 NEW PHARMACEUTICAL CHOLINE PHENOFIBRATE COMPOSITIONS

Country Status (2)

Country Link
TR (1) TR201111143T1 (en)
WO (1) WO2010131265A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104473909A (en) * 2014-11-21 2015-04-01 哈尔滨圣吉药业股份有限公司 Choline fenofibric acid sustained release pellets and preparation method thereof
CN105748445A (en) * 2016-03-31 2016-07-13 武汉药谷生物工程有限公司 Preparation method of choline fenofibrate acid sustained release capsule

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
CN101217944A (en) * 2005-04-08 2008-07-09 艾博特公司 Pharmaceutical formulations comprising fenofibric acid and/or its salts
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
JP2011502140A (en) * 2007-10-29 2011-01-20 ルピン・リミテッド Controlled release pharmaceutical composition of tolterodine

Also Published As

Publication number Publication date
WO2010131265A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
BRPI0913587A2 (en) Composition, pesticidal agent, method for controlling phytopathogenic harmful funds, seed, use of one compound and another compound, and, composition.
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
WO2010047765A3 (en) Nanostructures for drug delivery
WO2012027065A3 (en) Combination therapy for treatment of disease
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
SI1906939T1 (en) Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values
EP3207946A3 (en) Compositions comprising honey and a super-absorbent material
ES2556585T3 (en) Compositions comprising salbutamol sulfate
MX350380B (en) Zero-order modified release solid dosage forms.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
HK1140972A1 (en) Novel agent for releasing active principles in dressings containing at least one fatty substance
UA104866C2 (en) Ocreotide implant having a release agent
BR112013015796A2 (en) imaging agent composition, method of preparing an imaging agent composition, method of preparing an 18f-note chelator, and, pharmaceutical composition.
MX2014005514A (en) Tooth film formulations.
WO2010027676A3 (en) Dental composition comprising biphenyl di(meth)acrylate monomer
CL2007003356A1 (en) COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
CL2007001838A1 (en) COMPOUNDS DERIVED FROM 4-OXOQUINOLINE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE PRODUCTION OF AN ANTI-HIV AGENT.
WO2011101866A3 (en) Gastric retention formulation containing baclofen
BRPI0807285A2 (en) "COMPOSITION, METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION, UNIT FORM OF DOSAGE, METHOD FOR ADMINISTRATING A BIOLOGICAL ACTIVE AGENT NEEDING THE AGENT, METHOD FOR INCREASING BIODISPONABILITY FOR PREPARING AN AGENT OF COMPOSITION"
BR112013004493A2 (en) method for producing an agricultural product, use of a composition, and method for increasing the effectiveness of an agricultural chemical.
BR112012025066A2 (en) fluidizing mixture for hydraulic composition
WO2011077239A3 (en) Slow release pharmaceutical compositions of iloperidone
MX2007013327A (en) Extended release formulations.
JP2008541745A5 (en)
MX2010008852A (en) Formulations of flibanserin.